文献速递泌尿男性生殖肿瘤支持与姑息治疗

无症状不可治愈前列腺癌患者立即与延迟雄激素剥夺治疗的健康相关生活质量(TROG 03.06和VCOG PR 01-03 [TOAD]):一项随机、多中心、非盲、3期试验

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-07-28

TOAD试验在澳大利亚、新西兰和加拿大29个中心纳入293例仅PSA复发或新发不可治愈无症状前列腺癌患者,随机1:1接受立即或延迟雄激素剥夺治疗。5年内两组总体健康相关生活质量、躯体功能、角色功能、情绪功能、疲劳、呼吸困难、失眠及男性感无显著差异;立即治疗组在6和12个月性活动评分更低、激素治疗相关症状更多,潮热和乳头或乳房症状在5年内临床显著更高。

要点

  • 立即与延迟雄激素剥夺治疗在5年内总体健康相关生活质量无显著差异。
  • 立即治疗组6和12个月性活动评分更低,差异超过10分临床显著阈值至2年后。
  • 立即治疗组潮热和乳头或乳房症状在5年内临床显著更高。

核心结论

  • 立即使用雄激素剥夺治疗与特定激素治疗相关症状的早期损害相关,但对总体功能或健康相关生活质量无其他可证实的影响。
  • 该证据可用于帮助该疾病阶段男性关于治疗启动的决策。

研究设计与样本

  • 随机、多中心、开放标签、3期试验,在澳大利亚、新西兰和加拿大29个公立和私立癌症中心进行。
  • 纳入仅PSA复发或新发不可治愈无症状前列腺癌男性,随机1:1接受立即或延迟雄激素剥夺治疗,允许任何类型及间歇或持续方案。
  • 共招募293例男性,延迟治疗组151例,立即治疗组142例。
  • 使用EORTC QLQ-C30和PR25问卷在随机化前、2年内每6个月及随后3年每年完成,分析按意向治疗。
  • 主要终点总生存期已先前报告,此处报告预设次要目标生活质量终点,统计学显著性设为p=0.0036。

主要发现

  • 随机化后2年内两组总体健康相关生活质量无差异。
  • 随机化后整个5年内,总体生活质量、躯体功能、角色功能、情绪功能、疲劳、呼吸困难、失眠或感觉较少男性化无统计学显著差异。
  • 6个月时性活动平均评分延迟组29.20(95%CI 24.59-33.80) vs 立即组10.40(6.87-13.93),差异18.80(95%CI 13.00-24.59),p<0.0001;12个月时28.63(24.07-33.18) vs 13.76(9.94-17.59),差异14.86(8.95-20.78),p<0.0001;差异超过10分临床显著阈值至2年后。
  • 6个月时激素治疗相关症状平均评分延迟组8.48(95%CI 6.89-10.07) vs 立即组15.97(13.92-18.02),差异-7.49(-10.06至-4.93),p<0.0001;12个月时9.32(7.59-11.05) vs 17.07(14.75-19.39),差异-7.75(-10.62至-4.89),p<0.0001;差异低于临床显著阈值。
  • 5年期间潮热调整比例延迟组0.31 vs 立即组0.55,调整OR 2.87(1.96-4.21),p<0.0001;乳头或乳房症状0.06 vs 0.14,OR 2.64(1.61-4.34),p=0.00013。

临床怎么用

  • 作者认为该证据可用于帮助该疾病阶段男性关于治疗启动的决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen-deprivation therapy in patients with prostate cancer who have relapsed with rising prostate-specific antigen concentration only (PSA-only relapse), or with non-curable but asymptomatic disease at diagnosis, could adversely affect quality of life at a time when the disease itself does not. We aimed to compare the effect of immediate versus delayed androgen-deprivation therapy on health-related quality of life over 5 years in men enrolled in the TOAD (Timing of Androgen Deprivation) trial. METHODS: This randomised, multicentre, open-label, phase 3 trial done in 29 public and private cancer centres across Australia, New Zealand, and Canada compared immediate with delayed androgen-deprivation therapy in men with PSA-only relapse after definitive treatment, or de-novo non-curable disease. Patients were randomly assigned (1:1) with a database-embedded, dynamically balanced algorithm to immediate androgen-deprivation therapy (immediate therapy group) or to delayed androgen-deprivation therapy (delayed therapy group). Any type of androgen-deprivation therapy was permitted, as were intermittent or continuous schedules. The European Organisation for Research and Treatment of Cancer (EORTC) quality-of-life questionnaires QLQ-C30 and PR25 were completed before randomisation, every 6 months for 2 years, and annually for a further 3 years. The primary outcome of the trial, reported previously, was overall survival, with global health-related quality of life at 2 years as a secondary endpoint. Here we report prespecified secondary objectives of the quality-of-life endpoint. Analysis was by intention to treat. Statistical significance was set at p=0·0036. The trial was registered with the Australian New Zealand Clinical Trials Registry, number ACTRN12606000301561, and ClinicalTrials.gov, number NCT00110162. FINDINGS: Between Sept 3, 2004, and July 13, 2012, 293 men were recruited and randomly assigned; 151 to the delayed therapy group and 142 to the immediate therapy group. There was no difference between the two groups in global health-related quality of life over 2 years from randomisation. There were no statistically significant differences in global quality of life, physical functioning, role functioning, or emotional functioning, fatigue, dyspnoea, insomnia, or feeling less masculine over the entire 5 years after randomisation. Sexual activity was lower in the immediate therapy group than in the delayed group at 6 and 12 months (at 6 months mean score 29·20 [95% CI 24·59-33·80] in the delayed group vs 10·40 [6·87-13·93] in the immediate group, difference 18·80 [95% CI 13·00-24·59], p<0·0001; at 12 months 28·63 [24·07-33·18] vs 13·76 [9·94-17·59], 14·86 [8·95-20·78], p<0·0001), with the differences exceeding the clinically significant threshold of 10 points until beyond 2 years. The immediate therapy group also had more hormone-treatment-related symptoms at 6 and 12 months (at 6 months mean score 8·48 [95% CI 6·89-10·07] in the delayed group vs 15·97 [13·92-18·02] in the immediate group, difference -7·49 [-10·06 to -4·93], p<0·0001; at 12 months 9·32 [7·59-11·05] vs 17·07 [14·75-19·39], -7·75 [-10·62 to -4·89], p<0·0001), but with differences below the threshold of clinical significance. For the individual symptoms, hot flushes were clinically significantly higher in the immediate group (adjusted proportion 0·31 for delayed therapy vs 0·55 for immediate therapy, adjusted odds ratio 2·87 [1·96-4·21], p<0·0001) over the 5-year period, as were nipple or breast symptoms (0·06 vs 0·14, 2·64 [1·61-4·34], p=0·00013). INTERPRETATION: Immediate use of androgen-deprivation therapy was associated with early detriments in specific hormone-treatment-related symptoms, but with no other demonstrable effect on overall functioning or health-related quality of life. This evidence can be used to help decision making about treatment initiation for men at this disease stage. FUNDING: Australian National Health and Medical Research Council and Cancer Councils, The Royal Australian and New Zealand College of Radiologists, Mayne Pharma Australia, Tolmar Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Duchesne GM, Woo HH, King M, et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 2017. PMID: 28760403. doi:10.1016/S1470-2045(17)30426-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。